Attached files
| file | filename |
|---|---|
| EX-23.2 - EXHIBIT 23.2 - SUNOVION CNS DEVELOPMENT CANADA ULC | v433521_ex23-2.htm |
| EX-32.1 - EXHIBIT 32.1 - SUNOVION CNS DEVELOPMENT CANADA ULC | v433521_ex32-1.htm |
| EX-31.1 - EXHIBIT 31.1 - SUNOVION CNS DEVELOPMENT CANADA ULC | v433521_ex31-1.htm |
| EX-21.1 - EXHIBIT 21.1 - SUNOVION CNS DEVELOPMENT CANADA ULC | v433521_ex21-1.htm |
| EX-31.2 - EXHIBIT 31.2 - SUNOVION CNS DEVELOPMENT CANADA ULC | v433521_ex31-2.htm |
| EX-23.1 - EXHIBIT 23.1 - SUNOVION CNS DEVELOPMENT CANADA ULC | v433521_ex23-1.htm |
| 10-K - FORM 10-K - SUNOVION CNS DEVELOPMENT CANADA ULC | v433521_10k.htm |
Exhibit 16.1
March 9, 2016
United States Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549
Ladies and Gentlemen:
We have read Item 9 of Cynapsus Therapeutics Inc.’s (the “Company”) Annual Report on Form 10-K for the year ended December 31, 2015, and are in agreement with the statements contained in the second and third sentences of the first paragraph, and the second, third and fourth paragraphs, therein. We have no basis to agree or disagree with other statements of the Company contained therein.
Yours very truly,
McGOVERN, HURLEY, CUNNINGHAM, LLP
/s/ McGovern, Hurley, Cunningham, LLP
Chartered Accountants
Licensed Public Accountants